切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2017, Vol. 10 ›› Issue (05) : 559 -563. doi: 10.3877/cma.j.issn.1674-6902.2017.05.011

所属专题： 文献；

论著

同步放化疗治疗局部晚期EGFR野生型NSCLC合并COPD患者的临床疗效观察
杜建飞1, 畅婕1, 崔立春1, 王旋1, 党升强1, 张双燕1, 杨拴盈2,†()   
  1. 1. 710016　西安，长安医院肿瘤科
    2. 710004　西安，西安交通大学第二附属医院呼吸科
  • 收稿日期:2017-05-02 出版日期:2017-10-20
  • 通信作者: 杨拴盈
  • 基金资助:
    国家自然科学基金资助项目(81350032); 陕西省科技统筹计划重点项目(2014KTCL03-02)

Outcomes of concurrent thoracic radiation with chemotherapy for EGFR wild-type local advanced non small cell lung cancer with COPD

Jianfei Du1, Jie Chang1, Lichun Cui1, Xuan Wang1, Shengqiang Dang1, Shuangyan Zhang1, Shuanying Yang2,†()   

  1. 1. Department of Oncology, Changan Hospital, Xi′an 710016, China
    2. Department of Respiratory Disease, Second Affiliated Hospital of Xi′an Jiaotong University, Xi′an 710004, China
  • Received:2017-05-02 Published:2017-10-20
  • Corresponding author: Shuanying Yang
  • About author:
    Corresponding author: Yang Shuanying, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

杜建飞, 畅婕, 崔立春, 王旋, 党升强, 张双燕, 杨拴盈. 同步放化疗治疗局部晚期EGFR野生型NSCLC合并COPD患者的临床疗效观察[J/OL]. 中华肺部疾病杂志(电子版), 2017, 10(05): 559-563.

Jianfei Du, Jie Chang, Lichun Cui, Xuan Wang, Shengqiang Dang, Shuangyan Zhang, Shuanying Yang. Outcomes of concurrent thoracic radiation with chemotherapy for EGFR wild-type local advanced non small cell lung cancer with COPD[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(05): 559-563.

目的

探讨同步放化疗治疗局部晚期表皮生长因子受体(epidermal growth factor receptor, EGFR)野生型非小细胞肺癌(non-small cell lung cancer, NSCLC)合并慢性阻塞性肺病(chronic obstructive pulmonary disease, COPD)和肺不张患者的近期疗效及毒副反应。

方法

对42例局部晚期EGFR野生型NSCLC合并COPD和肺不张的患者给予低分割大剂量调强放射治疗，Dt：5Gy/次，隔日一次，3次/周，总剂量达到50～60Gy/10～12次，同步EP方案依托泊苷50 mg/m2 d1～5，顺铂d1～5(总量70 mg/m2)化疗，每四周为一周期，共化疗两周期后评估患者疗效。

结果

治疗结束后复查患者胸部CT评估患者肺部原发肿块及纵膈阳性淋巴结退缩情况完全缓解(complete remission, CR) 6例(14.3%)，部分缓解(partial remission, PR) 31例(73.8%)，稳定(stable disease, SD) 5例(11.9%)，进展(progressive disease, PD)0例；毒副反应情况：毒性反应主要表现为放射性肺炎，其中0级16例(38.1%)，Ⅰ～Ⅱ级21例(50%)，Ⅲ级5例(12%)。

结论

对于局部晚期EGFR野生型NSCLC合并COPD和肺不张的患者低分割调强放射治疗同步EP方案化疗安全有效，毒副反应可以耐受。

关键词: 同步放化疗, EGFR野生型, 局部晚期, 非小细胞肺癌, 肺疾病，慢性阻塞性
Objective

To explore the recent therapeutic effect and adverse reactions of chemoradiation for epidermal growth factor receptor(EGFR) wild-type LA-non-small cell lung cancer(NSCLC) patients with chronic obstructive pulmonary disease(COPD) and atelectasis.

Methods

42 patients receive hypofractionation Intensity-modulated radiotherapy, 5 Gy/ fraction, three times/week, total dose 50-60Gy/10-12fractions, Concurrent chemotherapy with etoposide 50 mg/m2 on days1 to 5 and cisplatin on days 1 to 5(total 70 mg/m2)every 4 weeks for two cycles.

Result

After treatment, 42 patients complete remission(CR) 6 cases(14.3%), partial remission(PR) 31 cases(73.8%), stable disease(SD) 5 cases(11.9%), progressive disease(PD) 0 case; Toxic effects mainly for radioactive pneumonia, of which the 0 level 16 cases (38.1%), Ⅰ-Ⅱ level 21 cases (50%), Ⅲ level 5 cases (12%).

Conclusion

hypofractionation Intensity-modulated radiotherapy Concurrent EP chemotherapy is effective and well-tolerated for EGFR wild-type LA-NSCLC patients with COPD and atelectasis.

Key words: Chemoradiation, EGFR wild-type, Local advanced, Non-small cell lung cancer, Chronic obstructive pulmonary disease
表1 42例肺癌合并COPD患者放化疗的近期疗效
疗　效 ≤5 cm(n＝25) >5 cm(n＝17) 合计(n＝42)
例数 构成比(%) 例数 构成比(%) 例数 构成比(%)
CR 3 12.00 3 17.65 6 14.29
PR 21 84.00 10 58.82 31 73.81
SD 1 4.00 4 23.53 5 11.90
PD 0 0.00 0 0.00 0 0.00
表2 患者治疗前后肺功能比较
组　别 例数 FEV1 FEV1/FVC DLCO VC FVC
治疗前 42 48.31±7.25 50.16±8.56 53.02±6.72 53.6±6.2 51.45±7.12
治疗后 42 67.24±6.32 66.21±5.23 67.23±7.01 67.4±6.45 66.82±5.85
P值 ? <0.05 <0.05 <0.05 <0.05 <0.05
表3 放射性肺炎发生率
级　别 例数 百分比(%)
0级 16 38.1
Ⅰ级 12 28.6
Ⅱ级 9 21.4
Ⅲ级 5 12
Ⅳ级 0 0
1
钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
2
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
3
任成山，钱桂生. 慢性阻塞性肺疾病发病机制研究现状与展望[J/CD]. 中华肺部疾病杂志(电子版), 2009, 2(2): 104-115.
4
Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014[J]. Arch Bronconeumol, 2014, 50 Suppl 1: 1-16.
5
任成山，白莉，钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2): 137-142.
6
Steuer CE, Behera M, Ernani V, et al. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage Ⅲ Non-Small-Cell Lung Cancer: A Systematic Review[J]. JAMA Oncol, 2017, 3(8): 1120-1129.
7
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
8
Yin P, Wang H, Vos T, et al. A Subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013[J]. Chest, 2016, 150(6): 1269-1280.
9
Durham AL, Adcock IM. The relationship between COPD and lung cancer [J]. Lung Cancer, 2015, 90(2): 121-127.
10
Hecht SS, Carmella SG, Murphy SE, et al. Tobacco smoke toxicant and carcinogen biomarkers and lung cancer susceptibility in smokers[J] J Thorac Oncol, 2016, 11(2): S7-S8.
11
Kohansal R, Martinez-Camblor P, Agustí A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort [J]. Am J Respir Crit Care Med, 2009, 180(1): 3-10.
12
Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer[J]. Ann Intern Med, 1987, 106(4): 512-518.
13
Yang P, Allen MS, Aubry MC, et al. Clinical features of 5，628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003[J]. Chest, 2005, 128(1): 452-462.
14
石远凯，孙燕，于金明，等. 中国晚期原发性肺癌诊治专家共识(2016年版)[J]. 中国肺癌杂志，2016, 19(1): 1-15.
15
Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights：non-small cell lung cancer, version 4.2016[J]. J Natl Compr Canc Netw, 2016, 14(3): 255-264.
16
Baumann M, Appold S, Petersen C, et al. Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer [J]. Lung cancer, 2001, 33 Suppl 1: S35-S45.
17
Liang J, Bi N, Wu S, et al. Etoposide and Cisplatin vs Paclitaxel and Carboplatin With Concurrent Thoracic Radiotherapy in Unresectable Stage Ⅲ Non-Small Cell Lung Cancer: A Multicenter Randomized Phase Ⅲ Trial[J]. Ann Oncol, 2017, 28(4): 777-783.
18
Sekine Y, Hata A, Koh E, et al. Lung carcinogenesis from chronic obstructive pulmonary disease: characteristics of lung cancer from COPD and contribution of signal transducers and lung stem cells in the inflammatory microenvironment[J]. Gen Thorac Cardiovasc Surg, 2014, 62(7): 415-421.
19
Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2013, 85(2): 444-450.
20
Dang J, Li G, Lu X, et al. Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy [J]. J Cancer Res Clin Oncol, 2010, 136(8): 1169-1178.
21
Shi A, Zhu G, Wu H, et al. Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy[J]. Radiat Oncol, 2010, 5(1): 35.
22
Warner A, Dahele M, Hu B, et al. Factors associated with early mortality in patients treated with concurrent chemoradiation therapy for locally advanced non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 94(3): 612-620.
23
Kim M, Lee J, Ha B, et al. Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer [J]. Radiat Oncol J, 2011, 29(3): 181-190.
[1] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[2] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[3] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[4] 赖淼, 景鑫, 李桂珍, 李怡. 非小细胞肺癌EGFR 突变亚型的临床病理和预后意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 731-737.
[5] 梁丽斯, 李洁, 贺帅, 来艳君, 刘铭, 张琳. MMP-9、MMP-2 及TLR4、HE4对非小细胞肺癌早期诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 756-761.
[6] 张礼江, 沈玲佳, 施我大. 倾向性评分匹配分析奥希替尼对晚期NSCLC 预后的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 820-822.
[7] 马锦芳, 何正光, 郑劲平. 盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病黏痰症患者的疗效和安全性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 568-574.
[8] 程炜炜, 张青, 张诚实, 冯契靓, 陈荣荣, 赵云峰. 全身免疫炎症指数与慢性阻塞性肺疾病急性加重期病情严重程度相关性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 580-584.
[9] 杨万荣, 任治坤, 时新颍. 沙丁胺醇雾化吸入脾多肽治疗AECOPD的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 609-612.
[10] 赖乾德, 吕相琴, 蔺洋, 刘媛梅, 赵春艳, 李琦. 肝素结合蛋白对慢性阻塞性肺疾病预后预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 613-616.
[11] 王微, 丁霖, 陈茜, 呼延欣, 闫蓓. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 621-624.
[12] 方晓玉, 王婷, 赵珊, 陈锋. HALP指数对AECOPD并发呼吸衰竭患者ICU结局的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 639-641.
[13] 郭少琳, 郭建英, 左秀萍, 高苗. 慢性阻塞性肺疾病康复训练依从性影响因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 652-654.
[14] 白若靖, 郭军. 维生素D对肺部疾病临床意义的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 659-662.
[15] 崔伟, 李静, 陈晓明, 张靖, 邓屹, 许荣德. 载药微球支气管动脉化疗栓塞术治疗非小细胞肺癌的研究进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 289-295.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？